Your browser is no longer supported. Please, upgrade your browser.
Settings
NVO Novo Nordisk A/S daily Stock Chart
NVO [NYSE]
Novo Nordisk A/S
Index- P/E20.88 EPS (ttm)2.13 Insider Own26.40% Shs Outstand2.00B Perf Week-2.84%
Market Cap88.92B Forward P/E18.18 EPS next Y2.44 Insider Trans0.00% Shs Float1.36B Perf Month-5.17%
Income5.43B PEG1.92 EPS next Q0.58 Inst Own10.00% Short Float0.15% Perf Quarter-11.90%
Sales16.62B P/S5.35 EPS this Y34.30% Inst Trans-1.68% Short Ratio0.83 Perf Half Y-17.47%
Book/sh2.53 P/B17.56 EPS next Y6.49% ROA41.50% Target Price57.00 Perf Year-16.90%
Cash/sh1.15 P/C38.79 EPS next 5Y10.90% ROE84.90% 52W Range44.04 - 57.43 Perf YTD-21.40%
Dividend1.41 P/FCF28.68 EPS past 5Y22.40% ROI85.00% 52W High-22.63% Beta0.71
Dividend %3.17% Quick Ratio0.90 Sales past 5Y12.20% Gross Margin84.80% 52W Low0.89% ATR0.75
Employees42265 Current Ratio1.30 Sales Q/Q1.50% Oper. Margin43.40% RSI (14)29.85 Volatility1.23% 1.32%
OptionableYes Debt/Eq0.01 EPS Q/Q21.50% Profit Margin32.70% Rel Volume0.78 Prev Close44.88
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout45.20% Avg Volume2.48M Price44.43
Recom3.00 SMA20-3.48% SMA50-9.53% SMA200-15.37% Volume1,939,898 Change-1.00%
Sep-23-16Initiated Piper Jaffray Neutral
Sep-13-16Upgrade Exane BNP Paribas Neutral → Outperform
Sep-09-16Downgrade JP Morgan Overweight → Neutral
Sep-01-16Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-31-16Upgrade HSBC Securities Reduce → Hold
Aug-08-16Downgrade BofA/Merrill Buy → Neutral
Aug-28-15Initiated Leerink Partners Mkt Perform $56
Jun-09-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-15-15Initiated Societe Generale Sell
May-28-13Upgrade Deutsche Bank Sell → Hold
Mar-31-10Initiated Deutsche Bank Hold
Mar-30-10Downgrade Mehta Partners Outperform → Market Perform
Feb-24-10Upgrade Jefferies & Co Hold → Buy
Jan-15-10Downgrade Jefferies & Co Buy → Hold
Sep-11-09Initiated Jefferies & Co Buy
Aug-07-09Downgrade UBS Buy → Neutral
Aug-07-09Downgrade JP Morgan Overweight → Neutral
May-12-09Initiated Piper Jaffray Buy
Apr-24-09Upgrade Citigroup Hold → Buy
Mar-26-09Upgrade UBS Neutral → Buy
Sep-23-16 07:15AM  Coverage initiated on Novo Nordisk A/S by Piper Jaffray
Sep-21-16 11:30AM  Novo Nordisk to supply insulin at discount to poorest nations Reuters
Sep-19-16 04:25AM  Holy Grail of Oral Insulin Gives Way to Other Tablets at Novo at Bloomberg
Sep-17-16 03:00PM  There's something odd about the way insulin prices change
Sep-16-16 03:48AM  Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent
12:02AM  A 93-year-old drug that can cost more than a mortgage payment tells us everything that's wrong with American healthcare
Sep-15-16 12:36PM  Great Place to Work® and Fortune name Novo Nordisk as one of the country's best workplaces for women PR Newswire
11:11AM  A 93-year-old drug that some children can't live without tells us everything that's wrong with American healthcare
09:54AM  Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Sep-14-16 06:04PM  How Sanofis Various Franchises Performed in 2Q16
04:04PM  How Sanofis Franchises Could Perform into 2017
Sep-12-16 03:59PM  Novo Nordisk (NVO) Stock Advances, Deutsche Bank Upgrades
11:28AM  ETFs with exposure to Novo Nordisk A/S : September 12, 2016
11:04AM  After Spinning Off Hemophilia Business, Whats Next for Biogen?
09:24AM  Why Novo Nordisk Stock Dropped 18.9% in August at Motley Fool
01:01AM  Pills and Pens Bring Hope for Drug Companies in Diabetes Crunch
Sep-10-16 01:10PM  Barron's Picks And Pans: Vodafone, BorgWarner, Novo Nordisk And More
01:04PM  NOVO NORDISK A S Financials
12:01AM  A Preview of This Weekend's Barron's at Barrons.com
12:01AM  [$$] Denmark's Novo Nordisk Plots a Recovery at Barrons.com
Sep-09-16 04:04PM  GlaxoSmithKlines Fundamentals Show It Has Lots of Room to Run
01:50PM  Inside The FDA: Eli Lilly and Co (LLY) Jardiance Aims at Proving Cardiovascular Benefit in Diabetes, Will FDA Agree? at Insider Monkey
08:14AM  Pharma Stock Roundup: Drug Pricing Remains in Focus, Merck Drops Odanacatib
Sep-07-16 07:04PM  Want to Know Why DISAX Has Done Well Year-to-Date?
Sep-06-16 01:38PM  Inside the FDA: Why Sanofi SA (ADR) (SNY) IGlarLixi Was Delayed But Novo Nordisk A/S (ADR) (NVO) IDegLira Wasnt at Insider Monkey
Sep-05-16 08:31AM  Novo Nordisk's IDegLira Review Period Extended in the U.S.
08:00AM  VeriFone (PAY), Gilead (GILD) Among 5 Stocks That Hit 52-Week Lows Last Week at Insider Monkey
Sep-02-16 12:52PM  [$$] Lars Fruergaard Jorgensen a model for 'Novo Nordisk Way' at Financial Times
08:04AM  Analyzing Eli Lillys Blockbuster Endocrinology Drugs
Sep-01-16 12:49PM  [$$] Novo Nordisk: long Lars-ting at Financial Times
12:40PM  [$$] Novo Nordisk chief executive retires in shake-up at Financial Times
11:32AM  Novo Nordisk (NVO) Stock Falls, CEO Rebien Sorensen Retires
10:11AM  Novo Taps Veteran as CEO to Tackle Unprecedented Competition at Bloomberg
09:42AM  Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down
06:17AM  Novo Nordisk CEO to step down after 16 years
02:11AM  Novos Chief to Retire, Veteran Joergensen to Succeed Him at Bloomberg
Aug-26-16 08:20AM  Sanofi Just Cant Catch a Break, Knocking at Major Support Again at 24/7 Wall St.
Aug-24-16 09:04AM  Why Did Novo Lower 2016 Sales Guidance?
Aug-23-16 07:04PM  Performance of AstraZenecas Growth Platforms in 2Q16
11:04AM  Whats Challenging Novos Leadership in the US Diabetes Space?
09:04AM  What Are the Prospects for Novos Biopharmaceuticals Segment?
Aug-22-16 01:14PM  Why Did Novos Valuation Multiple Fall Recently?
01:14PM  How Did Novos Diabetes and Obesity Care Segment Perform in 1H16?
11:54AM  FDAs Sanofi SA (ADR) (SNY) Delay Highlights Some Red Flags With IGlarLixi at Insider Monkey
11:48AM  ETFs with exposure to Novo Nordisk A/S : August 22, 2016
09:05AM  Can Allergan Generics Boost Teva Pharmaceuticals 2016 Revenues?
Aug-17-16 05:05PM  Inside Sanofis Valuation Changes
Aug-16-16 02:30PM  Novo Nordisk A/S Focuses on New Drugs at Motley Fool
Aug-15-16 07:30AM  Emisphere Reports Second Quarter 2016 Financial Results GlobeNewswire
Aug-14-16 07:18AM  3 Beaten-Up Big Pharma Stocks: Are They Bargains? at Motley Fool
Aug-12-16 01:17PM  Top 3 Research Reports for August 12, 2016
Aug-11-16 01:00PM  ETFs with exposure to Novo Nordisk A/S : August 11, 2016
Aug-10-16 10:18AM  Novo Nordisk A/S :NVO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
09:42AM  Post Earnings Coverage as Novo Nordisk Tops Profit Expectations with 23 Percent Growth
09:15AM  Post Earnings Coverage as Novo Nordisk Tops Profit Expectations with 23 Percent Growth Accesswire
09:07AM  An Update on Analyst Recommendations for Novo
Aug-09-16 03:40PM  How Did Novo Nordisk Perform across Geographies in 1H16?
03:40PM  A Look at Novos 2Q16 Revenue and Earnings
12:12PM  The Cryptic World of Oral Insulin, Novo Nordisk A/S (ADR) (NVO) vs Oramed Pharmaceuticals, Inc. (ORMP) at Insider Monkey
Aug-08-16 04:38PM  Stocks End Mildly Lower; MaxLinear Plunges After Hours; Inphi Rises -5.49%
07:53AM  Novo Nordisk (NVO) Beats Q2 Earnings, Revenues Up Y/Y
Aug-05-16 04:51PM  Novo Nordisk Plunges On Guidance Cut As Diabetes Sales Struggle -9.66%
09:14AM  European shares lifted by solid earnings but RBS slumps
05:20AM  Novo's insulin pill shows promise in mid-stage trial
05:02AM  Novo Nordisk beats 2Q profit forecasts
04:34AM  Novo Nordisk Shares Fall as It Trims Full-Year Guidance
04:16AM  Novo Nordisk Trims Full-Year Outlook
02:46AM  Novo Nordisk trims 2016 profit growth target
01:41AM  Novo Trims Full-Year Outlook Amid U.S. Price Pressure
01:41AM  Novo Nordisk Plummets Amid Pricing Challenges in U.S. Market at Bloomberg
Aug-04-16 11:40AM  Sam Isaly Adds to Stake in Novo Nordisk
Aug-02-16 04:09AM  Novos Victoza Diabetes Medicine Rebuffed by Express Scripts at Bloomberg
Aug-01-16 04:47PM  How Much Growth Will Novo See in 2Q16?
04:47PM  What Do Analysts Recommend for Novo?
Jul-28-16 07:15PM  Stocks With High Yield: Oracle, Cal-Maine, Infosys
Jul-26-16 10:55AM  European shares propped up by healthcare and consumer stocks
Jul-25-16 11:04AM  How Do the Majority of Analysts Rate Novartis after 2Q16?
Jul-22-16 04:11PM  Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
Jul-12-16 05:06PM  The CHMP Just Recommended the Extension of These Drugs Therapeutic Indications
03:26PM  My Favorite Health Care Stocks
Jul-08-16 12:01PM  *** DATA NOT AVAILABLE *** at noodls
Jul-06-16 11:40AM  Trump Or Hillary? Either Way, There's A Way To Profit at Forbes
Jun-30-16 07:06PM  Why Are Novo Nordisks Two Segments Growing?
04:06PM  What Are Analysts Thinking about Novo Nordisk?
09:20AM  Is $2.8 Billion Just The Beginning For This Novo Nordisk Diabetes Drug? at Motley Fool
Jun-29-16 09:07AM  Why Market Share for Novo Nordisks Tresiba Is Set to Grow
Jun-28-16 09:09AM  Could Novo Nordisks 2016 Earnings Impress Wall Street?
Jun-27-16 12:23PM  Evaluating Novo Nordisks Efficiency Based on EV-to-EBITDA
12:23PM  Novo Nordisks Premium Valuation Based on Price-to-Earnings
11:52AM  As Old Bestsellers Plateau, a Look at 4 Next Generation Diabetes Drugs at Insider Monkey
08:58AM  Research Report Initiated on Select Drug Manufacturers Equities
Jun-24-16 08:28AM  These 5 Stocks Could Be Toxic to Your Portfolio This Summer
Jun-22-16 03:37PM  How Big Is the Diabetes Treatment Market? at Motley Fool
12:20PM  The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All at Insider Monkey
Jun-20-16 08:38AM  What Is It About Novo Nordisk's Diabetes Drug That Makes It a Top Seller? at Motley Fool
07:59AM  5 Companies We'd Buy and Hold for the Next 20 Years at Motley Fool
Jun-18-16 09:03AM  Diabetes Deep-Dive: What Investors Need to Know About This Devastating Disease at Motley Fool
Jun-16-16 06:33PM  Why This Pharma Giant Lost $8 Billion in Market Cap This Week at Fortune
Jun-15-16 03:17PM  Novo Nordisk (NVO) Reports Positive Trial Results on Victoza
Jun-14-16 04:09PM  Novo Nordisk Drug Cuts Diabetic Deaths, But Not Enough For Wall Street
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents in North America, Europe, Japan and South Korea, China, Hong Kong, Taiwan, and other countries. Novo Nordisk A/S has a collaboration agreement with the Langer Laboratory. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.